Methods
We evaluated 968 consecutive diabetic patients undergoing PCI and treated with paclitaxel-eluting stent (PES) ( n = 580) and everolimus-eluting stent (EES) ( n = 388). In hospital, 1-month, 6-month, and 1-year clinical outcomes were analyzed and compared. Correlates of 1 year MACE were identified.
Results
Baseline characteristics were similar, except for more family history of CAD (53.6% vs. 46.1%, P = .02) in the PES group and more insulin-dependent diabetes and unstable angina at initial diagnosis in the EES group (35.3% vs. 29.0%, P = .04) and (55.9% vs. 46.4% P = .01), respectively. The PES group had higher number of lesions treated (1.6 ± 0.9 vs. 1.4 ± 0.6, P < .001), longer stents used (19.8 ± 6.1 vs. 18.3 ± 5.0, P < .001), and higher proportion of IVUS (64.2% vs. 54.4%, P < .001) and GP IIb/IIIa inhibitors used (5.4% vs. 2.3%, P = .02). The EES group had more type C and distal lesions. While there were no differences in the in-hospital events at l-month follow-up there was a higher TLR MACE in the PES group as well as higher rate of ST. ST continued to be higher in the PES group at 6 and 12 months and mortality was higher at 12 months in the PES group ( Table 1 ). After adjustment no significant differences were found between both types of stents on Cox regression analysis for hazard ratios in 1 year follow-up TLR MACE.
| Variable | PES ( n =580) | EES ( n =388) | P value |
|---|---|---|---|
| 30 days follow-up | |||
| TVR MACE | 20 (3.4%) | 6 (1.5%) | .07 |
| TLR MACE | 19 (3.3%) | 4 (1.0%) | .03 |
| Death | 13 (2.2%) | 4 (1.0%) | .16 |
| TLR | 5 (0.9%) | 0 (0.0%) | .09 |
| TVR | 8 (1.4%) | 2 (0.5%) | .33 |
| QWMI | 2 (0.3%) | 0 (0.0%) | .52 |
| NQWMI | 2 (0.3%) | 1 (0.3%) | 1.00 |
| ST | 8 (1.4%) | 0 (0.0%) | .03 |
| 6 months follow-up | |||
| TVR MACE | 55 (9.5%) | 28 (7.2%) | .21 |
| TLR MACE | 47 (8.1%) | 23 (5.9%) | .20 |
| Death | 32 (5.5%) | 15 (3.9%) | .24 |
| TLR | 17 (3.0%) | 8 (2.1%) | .40 |
| TVR | 27 (4.7%) | 13 (3.4%) | .32 |
| QWMI | 4 (0.7%) | 0 (0.0%) | .15 |
| NQWMI | 8 (1.4%) | 4 (1.0%) | .77 |
| ST | 9 (1.6%) | 0 (0.0%) | .01 |
| 1 year follow-up | |||
| TVR MACE | 93 (16.0%) | 56 (14.4%) | .50 |
| TLR MACE | 79 (13.7%) | 45 (11.7%) | .36 |
| Death | 54 (9.4%) | 20 (5.2%) | .02 |
| TLR | 27 (4.8%) | 25 (6.7%) | .23 |
| TVR | 43 (7.7%) | 37 (9.9%) | .24 |
| QWMI | 4 (0.7%) | 0 (0.0%) | .15 |
| NQWMI | 11 (2.0%) | 8 (2.2%) | .85 |
| ST | 9 (1.6%) | 0 (0.0%) | .01 |
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
